The Future of Cancer Therapy
Innovative science, breakthrough technology, first-in-class treatments
Pipeline
RGX-104
RGX-104 is a novel oral small molecule immunotherapy in development for the treatment of solid tumors, including drug-resistant malignancies.
Pipeline
RGX-202
RGX-202 is an oral small molecule cancer metabolism inhibitor in development for the treatment of gastrointestinal cancers, including colorectal and gastric cancer.
Pipeline
RGX-019
RGX-019 is a monoclonal antibody that targets a key pathway that drives tumor progression and metastasis of several cancer types, including triple-negative breast cancer.
Patients
Clinical Trials
We are actively recruiting patients for phase 1 first-in-human, dose escalation and expansion studies of RGX-104 and RGX-202.

Our Science
Science underlying Rgenix’s technology and pipeline has been published in leading scientific journals.
News
-
Translational and Clinical Development Strategies for IO Agents Targeting the Innate Immune System
Immuno-Oncology 360° | Crown Plaza Time Square, New York City | February 6, 2019 Masoud Tavazoie, Rgenix CEO and Co-Founder
-
Xconomy: New York Biotech – How to make it here
6:15-6:45 PM | The Rgenix Story: From our beginnings as a small spin-out from Rockefeller University to a world-class team with multiple
-
Rgenix CEO Masoud Tavazoie Discusses Immune System Regulation in Cancer at Plenary Session during AACR Meeting
On November 28, 2018, Masoud Tavazoie, Co-Founder and CEO of Rgenix, made a presentation at AACR’s Tumor Immunology and